Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Baijin Life Science Holdings Limited

佰金生命科學控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1466)

(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (2) CHANGE OF BOARD COMMITTEES MEMBERS; AND (3) COMPLIANCE WITH RULES 3.10(1), 3.21, 3.25 AND 3.27A OF THE LISTING RULES

The board of directors (the "**Board**") of Baijin Life Science Holdings Limited (the "**Company**") is pleased to announce that Ms. Shen Ding (沈定) has been appointed as an Independent Non-executive Director of the Company and a member of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company with effect from 2 March 2026.

Ms. Shen Ding, aged 38, has extensive experience in equity investment, asset management, and regulatory affairs. She served as the Assistant General Manager of Mingya Fund Management Co., Ltd.* (明亞基金管理有限責任公司) from 2022 to 2024, responsible for overseeing the end-to-end management of public funds and asset management products. From 2019 to 2022, she was the Deputy General Manager of Beijing Xiangyi Asset Management Co., Ltd.* (北京享億資產管理有限公司), responsible for establishing and maintaining pipelines for potential investment projects as well as conducting due diligence. Between 2013 and 2019, she worked as a supervising officer of China Securities Regulatory Commission, responsible for formulating and revising regulatory rules, supervising corporate information disclosure, and coordinating enforcement actions. From 2009 to 2013, she served as the Investment and Financing Manager at Beijing Changxin State-owned Asset Investment and Management Co., Ltd.* (北京昌鑫國有資產投資經營公司), responsible for handling government-related investment projects, capital operations and reporting of financing activity.

Ms. Shen graduated from China University of Political Science and Law (中國政法大學) with a degree in Business Administration and Law in 2009.

As at the date of this announcement, Ms. Shen does not have any relationship with any directors, senior management or substantial shareholders or controlling shareholders of the Company, and does not hold any other positions in the Company or any of its subsidiaries. She has not held any directorship in any listed companies in Hong Kong or overseas in the last three years and does not have any other major appointments and professional qualifications.

The Company has signed an appointment letter with Ms. Shen in respect of her directorship. There is no specific length of service for Ms. Shen pursuant to her appointment letter and she will hold office until the next following annual general meeting of the Company and shall then be eligible for re-election. Ms. Shen will also be subject to retirement by rotation and re-election pursuant to the articles of association of the Company.

Ms. Shen is entitled to a monthly remuneration of HK$18,000, which was determined by the Board on recommendation of the Remuneration Committee with reference to her qualifications, experience, duties and responsibilities with the Company, as well as the Company's performance and the prevailing market conditions.

As at the date of this announcement, Ms. Shen does not have any interests and short positions in the shares or underlying shares of the Company and its associated corporations which is required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board is of the view that Ms. Shen meets the independence requirements set out in Rule 3.13 of the Listing Rules.

Save as disclosed above, there are no other matters relating to the appointment of Ms. Shen that need to be brought to the attention of the shareholders of the Company, nor is there any information in respect of Ms. Shen which is required to be disclosed under Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**").

COMPLIANCE WITH RULES 3.10(1), 3.21, 3.25 AND 3.27A OF THE LISTING RULES

Following the appointment of Ms. Shen, the Board comprises three executive Directors, one non-executive Director and three independent non-executive Directors. As a result, the number of independent non-executive Directors meets with the requirements under Rule 3.10 of the Listing Rules.

Since Ms. Shen has been appointed as a member of the Audit Committee of the Company, the Company is in compliance with Rule 3.21 of the Listing Rules.

Since Ms. Shen has been appointed as a member of the Remuneration Committee of the Company, the Company is in compliance with Rule 3.25 of the Listing Rules.

Since Ms. Shen has been appointed as a member of the Nomination Committee of the Company, the Company is in compliance with Rule 3.27A of the Listing Rules.

The Board would like to take this opportunity to extend a warm welcome to Ms. Shen on taking up her new positions.

By order of the Board
BAIJIN LIFE SCIENCE HOLDINGS LIMITED
Cheung Sze Ming
Executive Director

Hong Kong, 2 March 2026

As at the date of this announcement, the Board comprises Mr. Cheung Sze Ming, Mr. Dong Peng and Dr. Su Yaoyao as executive Directors; Mr. Zhu Yongjun, Mr. Cheng Chi Kin and Ms. Xie Chunchen as non-executive Directors; Mr. Wong Siu Keung Joe, Mr. Chang Chunyu and Ms. Shen Ding as independent non-executive Directors.

* *For identification purposes only*